Trademark Overview
On Thursday, May 8, 2025, a trademark application was filed for ZYAMTIN with the United States Patent and Trademark Office. The USPTO has given the ZYAMTIN trademark a serial number of 99175897. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, May 8, 2025. This trademark is owned by uniQure biopharma B.V.. The ZYAMTIN trademark is filed in the Pharmaceutical Products category with the following description:
Biological preparations for medical use in medical and clinical gene therapy and cell therapy; clinical medical reagents for use in gene therapy, gene diagnosis, and gene testing; pharmaceutical preparations, namely, vaccines for use in gene therapy; pharmaceutical preparations for the treatment of Dravet's disease, Alzheimer's disease, ALS, Huntington's disease, Fragile X syndrome, Parkinson's disease, A1AT deficiency, epilepsy, temporal lobe epilepsy, focal cortical dysplasia, Fabry disease, multiple system atrophy, spinocerebellar ataxia and dyslipidemia; gene therapy and prophylaxis products, namely, gene-based biological preparations and medical reagents for use in gene regulation and gene modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, cancer, inflammatory and auto-immune diseases, vascular disorders, and single gene disorders.
